Druggable proteins influencing cardiac structure and function: Implications for heart failure therapies and cancer cardiotoxicity

Amand F. Schmidt, Mimount Bourfiss, Abdulrahman Alasiri, Esther Puyol-Anton, Sandesh Chopade, Marion van Vugt, Sander W. van der Laan, Christian Gross, Chris Clarkson, Albert Henry, Tom R. Lumbers, Pim van der Harst, Nora Franceschini, Joshua C. Bis, Birgitta K. Velthuis, Anneline S. J. M. te Riele, Aroon D. Hingorani, Bram Ruijsink, Folkert W. Asselbergs, Jessica van SettenChris Finan

Research output: Contribution to journalArticleAcademicpeer-review


Dysfunction of either the right or left ventricle can lead to heart failure (HF) and subsequent morbidity and mortality. We performed a genome-wide association study (GWAS) of 16 cardiac magnetic resonance (CMR) imaging measurements of biventricular function and structure. Cis-Mendelian randomization (MR) was used to identify plasma proteins associating with CMR traits as well as with any of the following cardiac outcomes: HF, non-ischemic cardiomyopathy, dilated cardiomyopathy (DCM), atrial fibrillation, or coronary heart disease. In total, 33 plasma proteins were prioritized, including repurposing candidates for DCM and/or HF: IL18R (providing indirect evidence for IL18), I17RA, GPC5, LAMC2, PA2GA, CD33, and SLAF7. In addition, 13 of the 25 druggable proteins (52%; 95% confidence interval, 0.31 to 0.72) could be mapped to compounds with known oncological indications or side effects. These findings provide leads to facilitate drug development for cardiac disease and suggest that cardiotoxicities of several cancer treatments might represent mechanism-based adverse effects.
Original languageEnglish
Pages (from-to)eadd4984
JournalScience advances
Issue number17
Publication statusPublished - 28 Apr 2023


  • Atrial Fibrillation
  • Cardiomyopathy, Dilated
  • Cardiotoxicity
  • Genome-Wide Association Study
  • Glypicans
  • Heart Failure
  • Humans
  • Neoplasms

Cite this